This group is a sub group of the IPEM Nuclear Medicine (formerly Radionuclide)

Special Interest Group and is fully supported by the BNMS and the

Nuclear Medicine Manufacturer's Association.

Current audit:      HMPAO SPECT audit

There has been considerable confusion about the impact on Nuclear Medicine practice following publication of HSC2000/026 Patient Group directions (England only) and the subsequent consultation document MLX 278 'Sale, Supply and Administration of Medicines by Health Professionals under Patient Group Directions'.  Specifically, the role of clinical scientists and MTO's as persons who administer drugs ( radiopharmaceuticals and/or non-radioactive prescription only medicines) as part of a protocol has been brought into question.

The UK Radiopharmacy Group (UKRG) has been active in trying to clarify the position and is now pleased to be able to report that new regulations have been introduced in the UK which explicity make it legal for an IR(ME)R operator to administer radiopharmaceuticals that have been authorised under protocol by the ARSAC certificate holder and also to administer associated non-active pharmaceuticals (such as frusemide) using IR(ME)R protocols, without the need to utilise Patient Group Directions.

Technologists Report 2006- 2007
Introduction
This has been a quiet year for the Technology Group. The effects of government targets, institutional changes etc have taken their toll. Consequently the group hasn’t been as active as I would have liked. The responsibility for this rests with me.
Cedric Eustance
Many of you know will know Cedric Eustance. Sadly following redundancy Cedric has left the UK’s shores for a career as a beach bum in Australia. Cedric has been a stalwart of the technologist community for many years (more than he’d like to admit to I’m sure).I’d like to extend heart-felt thanks of the Technology Group to Cedric for all his hard work over the years and to convey our best wishes for his future life down under.